Literature DB >> 26232306

Phenotyping and follow up of forty-seven Iranian patients with common variable immunodeficiency.

Saba Arshi1, Mohammad Nabavi1, Mohammad Hasan Bemanian1, Ramin Shakeri2, Behrang Taghvaei1, Babak Ghalebaghi3, Delara Babaie4, Ahmad Bahrami1, Morteza Fallahpour1, Hossein Esmaeilzadeh5, Mahsa Rekabi1, Javad Amadian1, Narjes Eslami1, Sima Shokri1, Farhad Jalali1, Nadieh Akbarpour1, Rasol Molatefi6, Nima Rezaei7.   

Abstract

BACKGROUND: Common variable immune deficiency (CVID) is a heterogeneous syndrome with a wide variety of signs and symptoms. This study describes the phenotyping and survival of the CVID patients in the allergy and clinical immunology department of Rasol-E-Akram Hospital of Iran University of Medical Sciences in Tehran.
METHOD: We retrospectively reviewed hospital files of CVID patients in our department until January 2014. All patients were diagnosed with standard diagnostic criteria of CVID, treated and visited monthly, during the follow-up period. We divided the patients into four phenotypes; infection only, cytopenia, polyclonal lymphocytic infiltration and unexplained enteropathy. The immunologic, demographic and clinical findings in different phenotypes were analysed.
RESULTS: The study included 47 CVID patients with mean age at onset of symptoms and diagnosis of 11.2 and 20.2 years, respectively. Phenotyping of our patients was: only infection (62%), cytopenia (26%) and PLI (19%) and 94% of cases had only one phenotype. We did not find a significant relation between the clinical phenotypes and immunologic or demographic data. Rate of parental consanguinity in our cases was 47%. Parental consanguinity was related to lower age at onset, lower age at diagnosis and higher baseline IgG levels. Patients with malignancy and autoimmunity had significantly higher age at onset. Our patients were followed-up for 6.9 years and the mortality rate during this time was 6%.
CONCLUSIONS: Parental consanguinity and age at onset of CVID symptoms may have important roles in CVID manifestations.
Copyright © 2015 SEICAP. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Age; Common variable immune deficiency (CVID); Consanguinity; Follow up; Iran

Mesh:

Year:  2015        PMID: 26232306     DOI: 10.1016/j.aller.2015.04.005

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  5 in total

Review 1.  Autoimmune Cytopenias in Common Variable Immunodeficiency Are a Diagnostic and Therapeutic Conundrum: An Update.

Authors:  Sanchi Chawla; Prabal Barman; Rahul Tyagi; Ankur Kumar Jindal; Saniya Sharma; Amit Rawat; Surjit Singh
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

Review 2.  Infectious Complications Reporting in Common Variable Immunodeficiency: A Systematic Review and Meta-analysis.

Authors:  Hamed Zainaldain; Fatema Sadaat Rizvi; Hosein Rafiemanesh; Mahla Alizadeh; Mahnaz Jamee; Sara Mohammadi; Fatemeh Kiaee; Hamed Mohammadi; Farhad Babaie; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi; Gholamreza Azizi
Journal:  Oman Med J       Date:  2020-07-30

3.  Severe Allergic Bronchopulmonary Mycosis and Long-Term Follow-Up.

Authors:  Hossein Esmaeilzadeh; Sara Kashef; Hamid Reza Hatami; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmaeilzadeh
Journal:  Case Reports Immunol       Date:  2018-08-12

4.  An immunocompetent patient with a nonsense mutation in NHEJ1 gene.

Authors:  Hossein Esmaeilzadeh; Mohammad Reza Bordbar; Zahra Hojaji; Parham Habibzadeh; Dorna Afshinfar; Mohammad Miryounesi; Majid Fardaei; Mohammad Ali Faghihi
Journal:  BMC Med Genet       Date:  2019-03-21       Impact factor: 2.103

5.  Aspirin Exacerbated Respiratory Disease and Nasal Polyp Phenotyping.

Authors:  Reza Kaboodkhani; Amirreza Bolkheir; Hossein Esmaeilzadeh; Mohammad Faramarzi; Mohammadjavad Ashraf; Milad Hosseinialhashemi; Negar Mortazavi; Narjes Ebrahimi
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.